WALTHAM, Mass. — Revvity, Inc. (NYSE: RVTY) said it has reached a definitive agreement to acquire ACD/Labs, a global provider of scientific software used to support analytical characterization and molecular design in pharmaceutical and material sciences. The deal is expected to expand the capabilities of Revvity Signals by strengthening how analytical data is translated into actionable scientific insights. The transaction is expected to close in late Q4 2025.
ACD/Labs specializes in tools that support analytical and process chemistry across research and development workflows. Its software is used to identify and characterize molecules, assess purity and quality, and support the development of scalable and reliable production processes. Combined, Revvity Signals and ACD/Labs aim to provide broader support across scientific discovery, development, and manufacturing, enabling researchers to interpret and manage complex data more efficiently.
Among the software capabilities ACD/Labs brings are the Spectrus Platform for advanced spectral analysis and the Percepta Platform for AI-driven prediction of molecular properties and ADMET. The company also offers tools for high-throughput experimentation (Katalyst D2D), decision support for pharmaceutical chemistry and manufacturing controls (Luminata), and enterprise-level analytical data management.
“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” said Kevin Willoe, president of Revvity Signals Software. “This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”
“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” said Daria Thorp, president and CEO of ACD/Labs. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software. Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”
